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Simple Summary: Uveal melanoma is a deadly form of eye cancer with a high rate of metastasis.
Once metastasis occurs, patients are often left with a short survival time, since there is no FDA
standard of care for the metastatic disease. Uveal melanoma develops from mutations mainly in
proteins involved in the Gq/11 signaling pathway, which drives pathogenesis. This review article
aims to summarize pre-clinical and clinical studies that have attempted to understand and treat
the disease by inhibiting the Gq/11 signaling pathway. We discuss the limited success of treatments
focused on downstream targets of the Gq/11 pathway and evaluate the effectiveness and feasibility of
treating the disease by directly inhibiting Gq/11 .
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Abstract: Uveal melanoma is the most common intraocular cancer in adults and arises from the
transformation of melanocytes in the uveal tract. While treatment of the primary tumor is often
effective, 36–50% of patients develop metastatic disease primarily to the liver. While various strategies
have been used to treat the metastatic disease, there remain no effective treatments that improve
survival. Significant insight has been gained into the pathways that are altered in uveal melanoma,
with mutually exclusive activating mutations in the GNAQ and GNA11 genes being found in over
90% of patients. These genes encode the alpha subunits of the hetetrotrimeric G proteins, Gq and G11 ,
and mutations result in activation of several important signaling pathways, including phospholipase
C and activation of the transcription factor YAP. In this review, we discuss current efforts to target
various signaling pathways in the treatment of uveal melanoma including recent efforts to target Gq
and G11 in mouse models. While selective targeting of Gq and G11 provides a potential therapeutic
strategy to treat uveal melanoma, it is evident that improved inhibitors and methods of delivery
are needed.
Keywords: cancer; G proteins; metastasis; signaling; uveal melanoma

Received: 7 November 2021
Accepted: 6 December 2021
Published: 9 December 2021

Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.

Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

1. Introduction
Uveal melanoma (UM) is the most common intraocular tumor in adults, and, as the
second most common form of melanoma, accounts for approximately 5% of all melanomas.
The median age at diagnosis is about 62 years, and risk factors include fair skin, light
eye color (green or blue), ocular melanocytosis, dysplastic nevus syndrome, germline
BRCA1-associated protein 1 (BAP1) mutations, and welding as an occupation [1–5]. UM
arises from melanocytes contained in the choroid, ciliary body, and iris (together known as
the uvea) of the ocular cavity, and has a high propensity to metastasize [6,7]. As a result,
36–50% of patients with UM develop metastasis, predominantly to the liver, even when the
primary tumor has successfully been eliminated [3,6,8–11]. While the primary tumor can
be successfully treated via enucleation, laser therapy, radiotherapy, or surgical resection,
many experts believe that the metastatic spread of UM is unpreventable, as it has likely
already taken place by the time the primary tumor is detected [8]. For instance, only 4%
of patients show detectable metastasis at the time of diagnosis of the primary tumor, but
up to half of all UM patients will develop metastatic disease. This suggests UM develops
small, undetectable metastases at an early stage of tumorigenesis, as early as 5 years
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prior to primary tumor detection, that remain dormant or quiescent for years, classifying
UM as a systemic disease requiring some form of systemic therapy [12–14]. Once macrometastasis develops, patients have a poor prognosis with a median overall survival time of
less than 1 year as there are currently no effective therapies with a significant impact on
survival [6,15–19].
To date, there is no FDA standard of care for metastatic UM. Systemic treatments that
have been successful in treating cutaneous melanoma (CM), such as chemotherapy and
immunotherapy, have largely failed to produce similar positive results in UM patients.
UM response rates to chemotherapy drugs such as dacarbazine, temozolomide, cisplatin,
treosulfan, and fotemustine range from 0% to 15%, and no agent has successfully prolonged
survival [20–24]. Moreover, immune checkpoint inhibitors of cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1), which significantly
improve survival outcomes for patients with advanced CM, have shown no clinical benefit
in patients with metastatic UM [25–28]. Additionally, while BRAF inhibitors show efficacy
in treating CM patients, UM remains unresponsive to similar treatments, despite both
malignancies originating from melanocytes derived from the neural-crest [7,29]. These
differences may be explained by the observation that UM has a distinctly different etiology
from CM. The main oncogenic BRAF and NRAS driver mutations in CM are not typically
found in UM [30–34], and while 80% of CM show a UV radiation mutational signature,
there is no observed evidence of the same in UM [26,35]. Furthermore, UM has an incredibly
low mutational burden compared to CM and most other cancer types [36,37]. With an
improved understanding of the genetic differences between cutaneous melanoma and
uveal melanoma, there is a clear need for more specific or targeted treatment strategies for
UM, as advances in CM treatment will be unlikely to confer the same results in UM.
2. Driver Mutations Involved in UM
UM predominantly involves mutually exclusive activating mutations in the GNAQ
or GNA11 genes that encode the highly conserved Gαq and Gα11 subunits of the heterotrimeric G-proteins [31,38,39]. The introduction of the oncogenic Gαq/11 mutants into
human or mouse melanocytes results in anchorage-independent growth and gives rise to
heavily pigmented tumors in mice [39–41]. Interestingly, while about 93% of cases contain
oncogenic Gαq or Gα11 , cases without such mutations often harbor activating mutations in
other genes linked to the Gq pathway. Activating mutations in PLCB4, which encodes for
the canonical Gq/11 effector phospholipase C β (PLCβ), or Cysteinyl Leukotriene Receptor
2 (CYSLTR2), a G protein-coupled receptor (GPCR) activator of Gq , are observed in 2.5%
and 4% of cases, respectively [26,36,42,43]. Taken together, it has become clear that aberrant
signaling via the Gq pathway is the main driver of uveal melanoma.
3. Gαq/11 Proteins and Their Mutations in UM
Gαq and Gα11 proteins are members of the Gq subfamily of Gα proteins, are 90%
homologous at the amino acid level, and are ubiquitously expressed. To maintain homeostasis in mammalian cells, the activation and deactivation of G-proteins is regulated
by tight control over GDP/GTP exchange and GTP hydrolysis rates. Ligand-activated
GPCRs, such as CysLTR2, act as guanine nucleotide exchange factors (GEFs) by stimulating
the exchange of GDP for GTP on the Gα subunit of the heterotrimeric G-protein. Upon
binding to GTP, the Gα subunit changes conformation, dissociates from the Gβγ dimer,
and interacts with downstream effectors, such as PLCβ and ARF6 [44–49]. Gα proteins
contain a Ras-like GTPase domain, wherein important amino acid residues provide the
subunit with intrinsic GTP hydrolytic activity, which is accelerated by the interaction of
GTPase-activating proteins (GAPs), such as regulators of G protein signaling (RGS). GTP
hydrolysis to GDP then terminates the Gα signaling, allowing the subunit to reassociate
with Gβγ and return to an inactive state [44,50,51].
The Gαq/11 mutations observed in uveal melanoma primarily occur at the Q209 and
R183 residues [31,38,39]. Both mutational hotspots are in the GTPase domain and are critical
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4.1. ARF6 Inhibition
ADP-ribosylation factor 6 (ARF6) is a small G-protein that has been shown to be
an immediate downstream effector of an activated GNAQ/GEP100 complex. ARF6 acts
as a proximal node of Gαq signaling to induce all the downstream pathways as well
as β-catenin signaling. ARF6 mediates the trafficking of Gαq from the cell membrane
to cytoplasmic vesicles and β-catenin to the nucleus. Inhibition of ARF6, by the ARF6
specific small-molecule inhibitor, NAV-2729, reduces uveal melanoma cell proliferation and
tumorigenesis in a mouse model [48]. Therefore, ARF6 is considered a potential therapeutic
target downstream of oncogenic Gαq .
4.2. PKC Inhibition
Activated Gαq canonically triggers the protein kinase C (PKC) pathway through
diacylglycerol produced by PLCβ activation [44]. Attempts to inhibit PKC in UM have
shown promise. The pan-PKC inhibitor, AEB071 (sotrastaurin), at low micromolar concentrations, significantly inhibits the growth of UM cells harboring GNAQ mutations, through
G1 arrest and apoptosis, and had little effect on UM cells carrying wild-type GNAQ [62].
A phase one study of AEB071 resulted in one achieved partial response, while 47% of
118 participants achieved disease stabilization and a median progression-free survival of
15.4 weeks although with some adverse effects [63]. This suggests there is some clinical
benefit of PKC inhibition and a new phase one study using the PKC inhibitor LXS196 is
currently underway (NCT02601378).
While PKC inhibitors inhibit MAPK signaling and induce G1 arrest in UM cells, they
fail to induce tumor regression in xenograft models. As a result, combination treatments
of PKC and MEK inhibitors have been attempted and have shown synergistic effects on
tumor regression in a UM in vivo model [64]. However, a phase one-b/two study of a PKC
and MEK combination treatment of patients with metastatic UM was halted before the
beginning of phase two (NCT01801358).
4.3. MAPK Pathway Inhibition
The drugs that have been used most often in an attempt to inhibit downstream Gq/11
signaling in UM are MEK inhibitors, because, similar to CM, MAPK signaling levels are
elevated in most UM [57]. Early studies showed MEK inhibitors, such as selumetinib
or TAK-733, successfully inhibit UM cell proliferation and viability in vitro [65]. These
studies resulted in several clinical trials with various MEK inhibitors, the first of which was
a comparison of selumetinib versus chemotherapy treatment, which showed improved
progression-free survival (15.9 vs. 7 weeks) but did not significantly improve overall
survival (9.1 vs. 11.8 months), while treatment-related adverse events were observed in 97%
of patients treated with selumetinib [66]. There is currently recruitment for a new phase one
trial to test the effect of intermittent selumetinib administration. The purpose of this study
is to test higher drug doses, to more completely block the MAPK pathway and prevent the
development of drug resistance mechanisms within the tumor. Intermittent administration
of the drug may also reduce side effects (NCT02768766). A phase one study using TAK733 also showed limited antitumor activity in patients with advanced solid tumors [67].
A recent review analyzed 590 case records from six eligible clinical trials, including the
study mentioned above [66]; a phase three study of selumetinib in combination with
dacarbazine [68]; phase two studies of selumetinib monotherapy versus temozolomide [69],
as well as trametinib, with or without GSK2141795 [70]; a phase one study of trametinib [71];
and a terminated phase one study of AEB071 and MEK162 (NCT01801358). The conclusion
is that UM is poorly responsive to MEK inhibitors, regardless of the inhibiting agent and
combination partner [72]. The failure of MEK inhibitors to provide meaningful effects
on overall survival and tumor growth may be explained by resistance mechanisms that
are enabled by the growth factors present in the liver tumor microenvironment [73,74].
However, these results have not deterred investigators from continuing to search for
effective combinations with selumetinib. A preclinical study of selumetinib in combination
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with the ERK inhibitor AZ6197, or the mTORC1/2 inhibitor AZD2014, displayed significant
efficacy in two PDX mouse models of UM [75]. Another recent study suggests chloroquine
or hydroxychloroquine sensitizes GNAQ/11-mutant UM to MEK inhibition by trametinib,
through the inhibition of autophagy or lysosome function. This combination treatment
synergistically inhibited tumor growth in metastatic mouse models [76].
While MAPK signaling is significantly upregulated in UM, and is often the target of
potential therapeutic interventions, the mechanism of how oncogenic Gαq/11 activates the
MAPK pathway is incompletely understood. The Ras guanyl releasing protein (RASGRP3)
is highly expressed in Gαq/11 -driven tumors, acts as a critical node for ERK activation, and
is activated via the PKC δ- and ε-isomers downstream of activated Gαq/11 in UM [77,78].
RASGRP3 is required for growth and Ras-MAPK activation in UM cells, as knockdown
of the gene transcript leads to decreased MAPK signaling and reduced growth in vitro
and in vivo [77,78]. Therefore, RASGRP3 is considered a potential therapeutic target
downstream of Gαq/11 and represents an additional avenue to MAPK inhibition specific
to UM.
4.4. PI3K/AKT/MTOR Inhibition
Another activated pathway downstream of oncogenic Gαq/11 that has been therapeutically targeted is the PI3K/AKT/MTOR pathway. This pathway is often targeted
in combination with MEK or PKC inhibition. One study showed that neither MEK nor
PI3K inhibition by trametinib or GSK2126458 alone was sufficient to induce apoptosis in
the majority of UM cell lines, but the combination of MEK and PI3K inhibitor treatment
resulted in a significant induction of apoptosis in a GNAQ/11 mutant-dependent manner [79]. Another study co-targeted PI3K and PKC inhibition with BYL719 and AEB071,
which showed synergistic inhibition of cell proliferation and apoptotic cell death in UM
cells, as well as a significant reduction in tumor growth, in a xenograft model [80]. As
a result, a phase one clinical trial of the efficacy and safety of BYL719 and AEB071 drug
combination in metastatic UM has begun, but its status is unknown (NCT02273219). Others
have targeted AKT in combination with MEK inhibition, which showed induced activation
of AMP-activated protein kinase, resulted in the synergistic induction of autophagic cell
death in UM cells, and inhibited UM tumor growth in xenograft mouse models [81]. This
evidence led to a phase two clinical trial, mentioned previously [70], of trametinib with
or without the AKT inhibitor GSK795, which failed to improve progression-free survival
compared to selumetinib treatment alone. Additionally, MTOR has also been targeted
in UM studies. A phase two clinical trial tested the combination of the MTOR inhibitor
everolimus, and the somatostatin receptor agonist pasireotide, in metastatic UM patients.
The combination showed little benefit and significant side-effects [82]. A preclinical study
found some success in the combination treatment of the MTOR inhibitor everolimus and
the PI3K inhibitor GDC0941, which provided increased apoptosis in UM tumors in two
PDX models [83]. Another study showed synergistic effects on tumor regression in UM
PDX models with a combination of the mTORC1 inhibitor RAD001 and the PKC inhibitor
AEB071 [84].
4.5. YAP Inhibition
The upregulation of yes-associated protein (YAP) driven by oncogenic Gαq/11 in UM
is a recent observation [40,41,85]. YAP is a co-transcriptional regulator involved in the
cell-growth-regulating Hippo pathway, which, when dephosphorylated, translocates from
the cytoplasm into the nucleus, where it associates with TEA domain transcription factor
(TEAD) to promote the transcription of growth promoting genes [86–89]. Studies have
shown that knockdown of Gαq/11 inactivates YAP, while YAP is required for mutant Gαq/11
driven tumorigenesis [40,41]. Further studies indicated that YAP dephosphorylation in
UM occurs through the Gαq/11 activation of Trio, a guanine nucleotide exchange factor
for the small G-proteins, RhoA and Rac1, independent of the Hippo pathway [41]. Additionally, the YAP inhibitor, verteporfin, can inhibit oncogenic Gαq/11 UM cell growth
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in mice [40,41,90]. Although these original studies suggest YAP as a potential therapeutic
target of UM, there has since been conflicting studies that suggest YAP may not be as
crucial to UM tumorigenesis as originally thought. One study investigating the association between YAP activity and clinical outcome concluded that the effect of YAP on the
development, growth, and invasion of UM in patients is less than previously found in
experimental studies [91]. Another study investigated the susceptibility of melanoma cell
lines to YAP inhibition by verteporfin and found that while most UM cell lines responded
in vitro to verteporfin, high risk metastatic UM lines (BAP1-negative) did not. Therefore,
the mutational background is an important predictor of response to YAP inhibition by
verteporfin, suggesting that not all UM cell lines are susceptible to YAP inhibition [92].
4.6. FAK Inhibition
Related to the Hippo pathway and YAP signaling, a recent study showed that Gαq
activates focal adhesion kinase (FAK), and that FAK activity is essential for YAP activation
and UM cell growth. Using an integrated bioinformatics pipeline, FAK was identified
as a candidate synthetic lethal gene with GNAQ activation. FAK inhibition, by small
molecules VS-4718 or PF562771, suppresses YAP activation in vivo and prevents UM cell
growth [93]. Unfortunately, MAPK signaling via oncogenic Gαq provides resistance to
FAK inhibition in UM cells. Therefore, a study wherein UM cells were treated with a
combination of the MEK inhibitor trametinib and the FAK inhibitor VS-4718 showed a
synergistic effect on metastatic UM tumor growth in a mouse model [94]. This study led
to a phase two clinical trial, which is currently recruiting metastatic UM patients, testing
the efficacy of the combination treatment of the RAF/MEK inhibitor VS-6766 and the
FAK inhibitor defactinib (VS-6063) (NCT04720417). Another recent study suggests that
PLCβ/PKC activity, but not FAK/YAP, is elevated in UM cell lines as a consequence of Gαq
pathway mutations, and that FAK may not be activated independent of PLCβ activation,
as previously suggested [95]. This study further illustrates that PKC/MAPK signaling is
essential for UM cell proliferation, and that only combined inhibition of PKC and MEK,
not FAK and MEK, or FAK and PKC, synergistically reduces cell viability in UM cells [95].
However, this was only shown in a few UM cell lines, and may not be true in every instance
of UM, as there is evidence to the contrary, as previously discussed. However, this study,
along with the observation that genetic analyses of UM have failed to identify mutations
in the FAK or YAP pathways, suggest that FAK or YAP may not be optimal targets for
therapeutic intervention in UM [26,96].
5. Direct Targeting of Gαq/11
Taken altogether, a potential explanation for these unsuccessful therapies is that oncogenic Gαq/11 activates multiple, individually dispensable downstream signaling networks.
Inhibition of one, or sometimes two, pathways does not achieve the desired treatment
outcome. This raises the possibility that direct inhibition of oncogenic Gαq/11 may be
an advantageous and promising therapeutic strategy for UM treatment. While there are
no current FDA-approved drugs that directly target Gαq/11 , a few compounds, namely
YM-254890 (YM) and FR900359 (FR) (Figure 2), that effectively inhibit Gαq/11 , have been
identified and have shown some promising results in pre-clinical UM studies [97,98].
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Figure 2. Chemical structures of Gq/11 depsipeptide inhibitors YM-254890 and FR900359. High-

Figure 2. Chemical structures of Gq/11 depsipeptide inhibitors YM-254890 and FR900359. Highlighted areas show the regions of YM-254890 and FR900359 that differ.
lighted areas show the regions of YM-254890 and FR900359 that differ.
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by this method via genetic engineering of Chromobacterium vaccinii DSM 25,150, with some
success [113]. However, chemical synthesis and biosynthesis methods result in very low
yields, leaving purification of the compound from natural sources as the main method of
production, as is the case for YM.
5.2. Mechanism of Action and Physiochemical Properties of YM and FR

In 2010, the structural basis for inhibition was revealed via an X-ray co-crystal struc-
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5.2. Mechanism of Action and Physiochemical Properties of YM and FR
In 2010, the structural basis for inhibition was revealed via an X-ray co-crystal structure
of YM bound to a chimeric Gαi/q βγ protein complex, showing that YM acts as a guanosine
nucleotide dissociation inhibitor (GDI) [114]. The structure revealed that YM binds to a
hydrophobic pocket between linker one and switch I of the Gαq subunit, with minimal
contact with Gβγ. The region in which linker one and switch I reside is between the helical
and GTPase domains and undergoes large conformational changes between the inactive
GDP-bound and active GTP-bound conformations. Upon binding of YM, the GDP-bound
state of Gαq is stabilized by suppression of the hinge motion of linker one and switch I,
resulting in the inhibition of the GDP/GTP exchange, leaving the Gαq protein “locked” in
the GDP-bound, inactive conformation [114].
In an effort to characterize FR, a comprehensive 2015 study used molecular dynamics
simulations, and a combination of purified proteins and cell-based assays, to show that
FR functions similarly to YM as a GDI of Gαq/11/14 proteins [107]. This same study
determined that FR inhibits Gαq activation in a pseudo-irreversible manner, and that its
effects are exceptionally resistant to washout in vasorelaxation and cell-based experiments.
Mutagenesis studies established that FR and YM bind to the same hydrophobic pocket of
Gαq , and that genetically engineered FR-binding sites can be used to create additional Gα
proteins, susceptible to FR inhibition, as an investigatory tool [115].
While YM and FR are very similar in their structure and mechanism of action, they
do show some biologically distinct activities. FR inhibits Gαq/11 with a 3-fold higher
potency than YM, and disruption of FR binding to Gαq is more difficult to achieve than
the binding of YM [103,115]. This difference in potency may be explained by physiochemical, kinetic, and molecular characteristics that the two very similar compounds do not
share. As explained previously, FR differs from YM by the addition of three methyl groups.
These differences make FR slightly larger and more lipophilic than YM. A conformational
study showed that while FR exists as a single conformer in aqueous solution, YM exists
as two different conformers in a major–minor (3:1) ratio. The major form is the biologically active conformer, while the minor represents a conformer that is unable to inhibit
Gαq [116]. This suggests that conformational stability is important to the inhibitory potency
of these compounds. Additionally, while both compounds display similar association rates
(t1/2 (FR) = 3.6 min versus t1/2 (YM) = 8.8 min), FR binds pseudo-irreversibly and displays
a residence time of 92.1 min, compared to 3.8 min for YM [117]. Molecular docking studies
seeking to explain this difference in dissociation rates suggest the additional lipophilic
moieties of FR anchor the compound in the binding pocket, similar to “a dowel forming
a latch”, while YM lacks those anchor points and may be more readily released from
the Gq protein [117]. This suggests that even small changes, which seem insignificant
within such a large and complex molecule, can lead to differences in potency and potential
pharmacological effects.
5.3. YM and FR Activity in Uveal Melanoma
Since the discovery of YM and FR, as potent Gq/11 inhibitors, it was believed that
the two compounds could inhibit only wild-type and R183 mutant proteins, but not Q209
mutants, which are almost always the driver mutations in UM. For example, the inhibitory
effect of YM on Gαq Q209L and R183C mutants was first tested in HEK293 cells, cotransfected with a serum response element (SRE)-luciferase reporter gene, and either Gαq
Q209L or R183C mutant cDNA. This study showed the constitutive activity of the R183C
mutant to be completely suppressed by YM, while that of the Q209L mutant was only
modestly affected [55]. A comprehensive characterization of FR as a Gαq/11/14 selective
inhibitor found that it was capable of inhibiting the Q209 mutant Gαq/11 [107]. In this study,
FR inhibited the growth of a mouse melanoma cell line, Hcmel12, which carries a Gαq Q209L mutation, and is wild type for B-Raf and N-Ras. FR was also found to effectively
inhibit nucleotide binding to purified Gαq -Q209L protein in vitro, suggesting FR directly
binds to the mutant Gαq/11 [118]. FR also inhibited the growth and proliferative signaling
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of UM cells containing oncogenic Gαq/11 proteins [118]. Additional studies investigating
similar effects of FR emerged around the same time [93,119–121] while research involving
YM treatment of UM have followed [95,122].
YM and FR show significant inhibitory activity against every mutant Gαq/11 variant
found in UM in transfected HEK293 cell-based experiments [121,122]. Both compounds
selectively inhibit cell growth and promote growth arrest of UM cells harboring oncogenic
Gαq/11 , as well as oncogenic cysteinyl leukotriene receptor 2 (CysLT2 RL129Q ) [93,95,118–122].
FR, and likely YM, target both primary and metastatic cells from UM tumors [121].
YM and FR selectively inhibit the essential oncogenic signaling of Gαq/11 mutant UM
cells. Treatment of UM cells with these Gq/11 inhibitors abolishes MAPK signaling, suppresses Akt activation, prevents YAP localization to the nucleus, and represses FAK
activation [93,95,118–122]. Class one UM cells (wild-type for BAP1) begin to express
melan-A at the plasma membrane and gain pigmentation when treated with low nanomolar concentrations of FR [118,119,121]. This suggests FR can induce a redifferentiation
of these cancer cells, possibly by decreasing Gq/11 activity to a level closer to that of a
normal melanocyte. It is believed that this FR-mediated redifferentiation is partly the
result of restored function to the polycomb repressive complex 2, which plays a role in
the differentiation of embryonic stem cells [119,121]. Concentrations of YM and FR at
100 nM and above selectively induce apoptosis and cell death of UM cells, as evidenced by
increased caspase-3 and PARP cleavage, as well as an increased population of cells in the
sub-G1 phase [95,118,119]. These Gq/11 inhibitors have shown great promise as potential
therapeutics in cell-based assays, but are these results recapitulated in vivo?
To address this, there are some recent studies wherein UM mouse models were treated
with YM and FR. The first of which showed that FR (0.5 mg/kg) treatment of severe
combined immunodeficient (SCID) mice with subcutaneously grafted Gαq Q209P UM cells
resulted in 72% tumor growth inhibition after 14 days, whereas the growth of xenografts
established from B-Raf mutant melanoma cells was unaffected [120]. A second recent study
using subcutaneous UM tumor xenografts of Gα11 Q209L and Gαq Q209L UM cells, established
in NOD-scid-gamma (NSG) mice, showed that FR inhibited the growth of UM tumors at
0.1 and 0.3 mg/kg, but had no effect on the growth of B-Raf mutant melanoma tumors [121].
However, UM tumors resumed growth 16 days after FR treatment was stopped, suggesting
that FR only causes reversible, rather than durable, arrest or regression of UM tumors.
ERK phosphorylation in xenograft tumors was only reduced by 30% compared to at least
85% observed in vitro, suggesting FR treatment does not completely suppress aberrant
MAPK signaling in vivo. However, FR treatment does provide a therapeutic window in
which tumors cells are targeted, while healthy cells maintain the correct physiological
Gq/11 signaling. It is possible the observed incomplete inhibition of MAPK signaling is the
result of a resistance or compensatory mechanism at work in these cells, as reverse-phase
protein analysis showed an increase of HER3 and activated STAT3 upon FR treatment
of UM cells in vitro [118]. Additionally, a recent study showed that YM, similar to FR,
inhibited tumor formation in mice with xenografts of Gαq Q209P UM cells [122]. Notably, it
was observed during this study that YM does not durably suppress MAPK signaling of
UM cells in vitro, and that MAPK signature genes begin to rebound after 24 h. This was
similarly observed in tumors treated with YM ex vivo. However, a combination strategy of
YM plus an MEK inhibitor was able to prevent reactivation and durably suppress MAPK
in UM xenograft mice, while the combination also worked synergistically to inhibit tumor
growth and promote tumor regression. Taken together, the current in vivo studies suggest
Gq/11 inhibition as a viable therapeutic strategy to treat UM; however, to achieve durable
arrest and regression of UM tumors, a combinatorial approach may be warranted.
5.4. Feasibility of Gq/11 Inhibitors as Potential Therapeutics
A recent study that sought to determine if YM and FR are fit for translation, and provides a solid basis for considering future in vivo investigations utilizing YM and FR [123].
It was determined that both YM and FR have high chemical stability under physiological
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conditions, and both are high clearance compounds in human liver microsomes. However,
YM is more stable than FR in human liver microsomes, with short half-lives of 27.3 min
and 8.1 min, respectively. Due to the high clearance rate of these compounds, they may
not be suitable for systemic application. Importantly, in vivo studies showed that both
compounds are only marginally able to cross the blood-brain barrier. However, local administration of these compounds will be preferred, since systemic application can be expected
to block Gq/11 signaling throughout the body. In this regard, the Blumer group determined
a LD50 of approximately 0.6 mg/kg FR in NSG mice and showed that FR delivered at
tolerable doses did not significantly affect heart rate, liver function, or hematopoiesis in
xenograft UM models [121].
6. Discussion
Uveal melanomas are divided into class one (low metastatic risk) and class two (high
metastatic risk) based on gene expression profiling [124]. While almost all UM patients have
aberrations in the Gq/11 pathway, particularly in the Gαq/11 proteins, these mutations occur
early in tumorigenesis and are not correlated with molecular class or metastasis [31,125].
Class two tumors are strongly associated with an additional BAP1 mutation or deletion that
occurs after Gαq/11 mutation [5]. This additional mutation increases the metastatic potential
of UM, but aberrant Gq/11 signaling remains as the main driver of tumorigenesis. Recently,
the Blumer group has shown that both class one and class two tumor growth is inhibited
by Gq/11 inhibition by FR in UM xenografts [121]. This further strengthens the idea that
targeting oncogenic Gαq/11 can be a viable therapeutic strategy in treating all subtypes
of UM. Targeting oncogenic Gαq/11 has the additional benefit, over current monotherapy
strategies, of inhibiting the multiple signaling networks downstream of Gq/11 .
While Gq/11 inhibitors show promise as future therapeutic options, their potential use
presents a risk of adverse effects, as they act on both mutated and wild-type Gαq/11 proteins,
which are ubiquitously expressed and have important physiological functions [126–129].
Clearly, compounds that can selectively target mutationally activated Gαq/11 over wildtype Gαq/11 would be ideal as therapeutic agents, but these do not currently exist. However,
a growing body of work investigating the important moieties of YM and FR at the molecular
level and how these compounds interact with Gαq/11 , provides valuable insight into the
possible synthesis of such a compound. In an effort to synthesize YM, a few simplified YM
analogs were synthesized based on the motifs of YM that are thought to be important in
maintaining the compound’s stability and making contact with the Gαq protein [130,131].
Its successful synthesis, in 2016, led to the production of many additional analogs used to
probe the structure–activity relationship of YM, by modification of key structural elements
of the compound [103,116,132,133]. However, all the analogs are less potent than YM, and
it has become clear that even small structural changes result in reduced affinity for Gαq .
Many simplified analogs of FR have also been reported, and while a few selectively inhibit
Gq/11 at a comparable potency to FR, most have failed to inhibit Gq/11 , and none have
surpassed the biological activity of FR [116,134,135].
At present, the chemical and synthetic approaches to synthesizing YM and FR have
low yields and very complex procedures. Purification of the compounds is the only way
to obtain substantial quantities of YM and FR but is time consuming. However, having a
method of chemical synthesis provides an avenue to rationally modify these compounds,
determine crucial moieties for Gq/11 inhibition, and possibly design compounds that may
be able to more specifically target the oncogenic mutant Gαq/11 . Some have taken to using
biosynthesis methods of creating new YM/FR analogs [136], while others are utilizing
feature-based molecular networking techniques to identify new FR analogs produced by
other bacterial strains [135,137]. A recent study using tritium-labelled YM and FR compounds in a high throughput competition binding assay discovered novel Gq inhibitors,
which inhibited Gq signaling in recombinant cells and primary murine brown adipocytes,
resulting in enhanced differentiation, albeit with significantly less potency than FR [117].
Moreover, the group that first synthesized YM and FR has recently reported a new Gq/11
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inhibitor, GQ127, to be a potent, stable, and safe small molecule. It exhibits good Gq/11
protein inhibition and antitumor potency in vitro, and significantly inhibits in vivo tumor
growth of UM cells [138]. While GQ127 requires significantly higher concentrations compared to YM and FR to observe similar effects on UM cell signaling and tumor growth, it is
easily synthesized, displays high oral bioavailability, and shows no obvious side effects in
mice. Therefore, it may be an additional structure to build upon for future UM drugs that
target Gq/11 .
7. Conclusions
Uveal melanoma is a rare melanoma that is biologically distinct from cutaneous
melanoma and cannot be treated in a similar manner in the clinic. Despite a high level
of success in treating primary UM locally, 36–50% of patients will eventually develop
metastasis. To this point, the metastatic disease remains uncurable, and outcomes for
patients with UM metastasis are poor [17]. Single agents that target signaling pathways
downstream of mutated Gαq/11 are not effective, and there is a desperate need for better
treatment options. Combinational therapies that co-target multiple pathways are being
investigated. The emergence of the Gq/11 inhibitors YM-254890 and FR900359, and their
recent success in treating UM in preclinical studies, suggests that direct inhibition of
oncogenic Gαq/11 may be a viable approach, or at least provide a therapeutic window
to treat the disease more effectively with an additional drug, such as an MEK inhibitor
or an inhibitor of survival signals from the liver microenvironment. However, these
Gq/11 inhibitors act on both mutated and wild-type Gαq/11 proteins, which raises safety
concerns, as Gq/11 is ubiquitously expressed and has a number of important physiological
roles [126–129]. A local delivery system would be most advantageous, especially one that
is able to target the liver, as it is likely that micrometastasis has already formed by the
time of initial diagnosis. As we improve our understanding of how these compounds
function and interact with Gq/11 , the development of a compound that specifically targets
the activated mutant Gαq/11 may one day be possible.
Author Contributions: D.L., writing—original draft and editing; J.L.B., writing—review and editing.
All authors have read and agreed to the published version of the manuscript.
Funding: This work was supported by the Dr. Ralph and Marian Falk Medical Research Trust Bank
of America, N.A., Trustee and National Institutes of Health awards P01 HL114471 (to J. Benovic) and
F31 CA225064 (to D. Lapadula).
Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.
3.

4.
5.
6.
7.
8.

Weis, E.; Shah, C.P.; Lajous, M.; Shields, J.A.; Shields, C.L. The association between host susceptibility factors and uveal melanoma:
A meta-analysis. Arch. Ophthalmol. 2006, 124, 54–60. [CrossRef]
Shah, C.P.; Weis, E.; Lajous, M.; Shields, J.A.; Shields, C.L. Intermittent and chronic ultraviolet light exposure and uveal melanoma:
A meta-analysis. Ophthalmology 2005, 112, 1599–1607. [CrossRef]
Shields, C.L.; Kaliki, S.; Livesey, M.; Walker, B.; Garoon, R.; Bucci, M.; Feinstein, E.; Pesch, A.; Gonzalez, C.; Lally, S.E.; et al.
Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: Analysis of 7872 consecutive
eyes. JAMA Ophthalmol. 2013, 131, 993–1003. [CrossRef] [PubMed]
Hammer, H.; Oláh, J.; Tóth-Molnár, E. Dysplastic nevi are a risk factor for uveal melanoma. Eur. J. Ophthalmol. 1996, 6, 472–474.
[CrossRef]
Harbour, J.W.; Onken, M.D.; Roberson, E.D.; Duan, S.; Cao, L.; Worley, L.A.; Council, M.L.; Matatall, K.A.; Helms, C.; Bowcock,
A.M. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330, 1410–1413. [CrossRef] [PubMed]
Singh, A.D.; Bergman, L.; Seregard, S. Uveal melanoma: Epidemiologic aspects. Ophthalmol Clin N. Am 2005, 18, 75–84. [CrossRef]
[PubMed]
Arnesen, K. The neural crest origin of uveal melanomas. Int. Ophthalmol. 1985, 7, 143–147. [CrossRef] [PubMed]
Damato, B. Ocular treatment of choroidal melanoma in relation to the prevention of metastatic death-A personal view. Prog. Retin.
Eye Res. 2018, 66, 187–199. [CrossRef]

Cancers 2021, 13, 6195

9.

10.
11.

12.
13.

14.
15.
16.
17.
18.
19.

20.
21.
22.
23.

24.
25.

26.
27.
28.

29.
30.
31.
32.
33.
34.
35.

12 of 17

Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large
choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch. Ophthalmol. 2001,
119, 670–676. [CrossRef] [PubMed]
Kujala, E.; Mäkitie, T.; Kivelä, T. Very long-term prognosis of patients with malignant uveal melanoma. Investig. Ophthalmol.
Vis. Sci. 2003, 44, 4651–4659. [CrossRef]
Diener-West, M.; Reynolds, S.M.; Agugliaro, D.J.; Caldwell, R.; Cumming, K.; Earle, J.D.; Hawkins, B.S.; Hayman, J.A.; Jaiyesimi, I.;
Jampol, L.M.; et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma:
Collaborative Ocular Melanoma Study Group Report No. 26. Arch. Ophthalmol. 2005, 123, 1639–1643. [PubMed]
Eskelin, S.; Pyrhönen, S.; Summanen, P.; Hahka-Kemppinen, M.; Kivelä, T. Tumor doubling times in metastatic malignant
melanoma of the uvea: Tumor progression before and after treatment. Ophthalmology 2000, 107, 1443–1449. [CrossRef]
Callejo, S.A.; Antecka, E.; Blanco, P.L.; Edelstein, C.; Burnier, M.N. Identification of circulating malignant cells and its correlation
with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 2007, 21, 752–759. [CrossRef]
[PubMed]
Ossowski, L.; Aguirre-Ghiso, J.A. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res. 2010, 23, 41–56. [CrossRef]
Singh, A.D.; Turell, M.E.; Topham, A.K. Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology 2011,
118, 1881–1885. [CrossRef]
Park, J.J.; Diefenbach, R.J.; Joshua, A.M.; Kefford, R.F.; Carlino, M.S.; Rizos, H. Oncogenic signaling in uveal melanoma.
Pigment Cell Melanoma Res. 2018, 31, 661–672. [CrossRef]
Yang, J.; Manson, D.K.; Marr, B.P.; Carvajal, R.D. Treatment of uveal melanoma: Where are we now? Ther. Adv. Med. Oncol. 2018,
10, 1758834018757175. [CrossRef]
Rantala, E.S.; Hernberg, M.; Kivelä, T.T. Overall survival after treatment for metastatic uveal melanoma: A systematic review and
meta-analysis. Melanoma Res. 2019, 29, 561–568. [CrossRef]
Khoja, L.; Atenafu, E.G.; Suciu, S.; Leyvraz, S.; Sato, T.; Marshall, E.; Keilholz, U.; Zimmer, L.; Patel, S.P.; Piperno-Neumann,
S.; et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: An
international rare cancers initiative (IRCI) ocular melanoma study. Ann. Oncol. 2019, 30, 1370–1380. [CrossRef]
Spagnolo, F.; Caltabiano, G.; Queirolo, P. Uveal melanoma. Cancer Treat. Rev. 2012, 38, 549–553. [CrossRef]
Spagnolo, F.; Grosso, M.; Picasso, V.; Tornari, E.; Pesce, M.; Queirolo, P. Treatment of metastatic uveal melanoma with intravenous
fotemustine. Melanoma Res. 2013, 23, 196–198. [CrossRef]
Augsburger, J.J.; Corrêa, Z.M.; Shaikh, A.H. Effectiveness of treatments for metastatic uveal melanoma. Am. J. Ophthalmol. 2009,
148, 119–127. [CrossRef]
Schmittel, A.; Schmidt-Hieber, M.; Martus, P.; Bechrakis, N.E.; Schuster, R.; Siehl, J.M.; Foerster, M.H.; Thiel, E.; Keilholz, U. A
randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.
Ann. Oncol. 2006, 17, 1826–1829. [CrossRef]
Homsi, J.; Bedikian, A.Y.; Papadopoulos, N.E.; Kim, K.B.; Hwu, W.-J.; Mahoney, S.L.; Hwu, P. Phase 2 open-label study of weekly
docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res. 2010, 20, 507–510. [CrossRef]
Kelderman, S.; van der Kooij, M.K.; van den Eertwegh, A.J.M.; Soetekouw, P.M.M.B.; Jansen, R.L.H.; van den Brom, R.R.H.;
Hospers, G.A.P.; Haanen, J.B.A.G.; Kapiteijn, E.; Blank, C.U. Ipilimumab in pretreated metastastic uveal melanoma patients.
Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol. (Madr.) 2013, 52, 1786–1788. [CrossRef]
Robertson, A.G.; Shih, J.; Yau, C.; Gibb, E.A.; Oba, J.; Mungall, K.L.; Hess, J.M.; Uzunangelov, V.; Walter, V.; Danilova, L.; et al.
Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 2017, 32, 204–220.e15. [CrossRef]
Heppt, M.V.; Steeb, T.; Schlager, J.G.; Rosumeck, S.; Dressler, C.; Ruzicka, T.; Nast, A.; Berking, C. Immune checkpoint blockade
for unresectable or metastatic uveal melanoma: A systematic review. Cancer Treat. Rev. 2017, 60, 44–52. [CrossRef]
Mignard, C.; Deschamps Huvier, A.; Gillibert, A.; Duval Modeste, A.B.; Dutriaux, C.; Khammari, A.; Avril, M.-F.; Kramkimel, N.;
Mortier, L.; Marcant, P.; et al. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma. J. Oncol. 2018,
2018, 1908065. [CrossRef]
Luke, J.J.; Flaherty, K.T.; Ribas, A.; Long, G.V. Targeted agents and immunotherapies: Optimizing outcomes in melanoma.
Nat. Rev. Clin. Oncol. 2017, 14, 463–482. [CrossRef] [PubMed]
Rimoldi, D.; Salvi, S.; Liénard, D.; Lejeune, F.J.; Speiser, D.; Zografos, L.; Cerottini, J.-C. Lack of BRAF mutations in uveal
melanoma. Cancer Res. 2003, 63, 5712–5715. [PubMed]
Onken, M.D.; Worley, L.A.; Long, M.D.; Duan, S.; Council, M.L.; Bowcock, A.M.; Harbour, J.W. Oncogenic mutations in GNAQ
occur early in uveal melanoma. Investig. Ophthalmol. Vis. Sci. 2008, 49, 5230–5234. [CrossRef]
Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; et al.
Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949–954. [CrossRef]
Saldanha, G.; Purnell, D.; Fletcher, A.; Potter, L.; Gillies, A.; Pringle, J.H. High BRAF mutation frequency does not characterize all
melanocytic tumor types. Int. J. Cancer 2004, 111, 705–710. [CrossRef]
Hodis, E.; Watson, I.R.; Kryukov, G.V.; Arold, S.T.; Imielinski, M.; Theurillat, J.-P.; Nickerson, E.; Auclair, D.; Li, L.; Place, C.; et al.
A landscape of driver mutations in melanoma. Cell 2012, 150, 251–263. [CrossRef]
Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015, 161, 1681–1696. [CrossRef]

Cancers 2021, 13, 6195

36.

37.

38.
39.
40.
41.

42.

43.

44.
45.
46.
47.
48.

49.
50.
51.
52.
53.

54.
55.
56.

57.

58.
59.

60.

13 of 17

Johansson, P.; Aoude, L.G.; Wadt, K.; Glasson, W.J.; Warrier, S.K.; Hewitt, A.W.; Kiilgaard, J.F.; Heegaard, S.; Isaacs, T.;
Franchina, M.; et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 2016, 7, 4624–4631.
[CrossRef]
Furney, S.J.; Pedersen, M.; Gentien, D.; Dumont, A.G.; Rapinat, A.; Desjardins, L.; Turajlic, S.; Piperno-Neumann, S.;
de la Grange, P.; Roman-Roman, S.; et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma.
Cancer Discov. 2013, 3, 1122–1129. [CrossRef]
Van Raamsdonk, C.D.; Bezrookove, V.; Green, G.; Bauer, J.; Gaugler, L.; O’Brien, J.M.; Simpson, E.M.; Barsh, G.S.; Bastian, B.C.
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457, 599–602. [CrossRef]
Van Raamsdonk, C.D.; Griewank, K.G.; Crosby, M.B.; Garrido, M.C.; Vemula, S.; Wiesner, T.; Obenauf, A.C.; Wackernagel, W.;
Green, G.; Bouvier, N.; et al. Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 2010, 363, 2191–2199. [CrossRef]
Yu, F.-X.; Luo, J.; Mo, J.-S.; Liu, G.; Kim, Y.C.; Meng, Z.; Zhao, L.; Peyman, G.; Ouyang, H.; Jiang, W.; et al. Mutant Gq/11 promote
uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014, 25, 822–830. [CrossRef]
Feng, X.; Degese, M.S.; Iglesias-Bartolome, R.; Vaque, J.P.; Molinolo, A.A.; Rodrigues, M.; Zaidi, M.R.; Ksander, B.R.; Merlino, G.;
Sodhi, A.; et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho
GTPase signaling circuitry. Cancer Cell 2014, 25, 831–845. [CrossRef]
Moore, A.R.; Ceraudo, E.; Sher, J.J.; Guan, Y.; Shoushtari, A.N.; Chang, M.T.; Zhang, J.Q.; Walczak, E.G.; Kazmi, M.A.;
Taylor, B.S.; et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat. Genet.
2016, 48, 675–680. [CrossRef] [PubMed]
Ceraudo, E.; Horioka, M.; Mattheisen, J.M.; Hitchman, T.D.; Moore, A.R.; Kazmi, M.A.; Chi, P.; Chen, Y.; Sakmar, T.P.; Huber, T.
Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling.
J. Biol. Chem. 2021, 296, 100163. [CrossRef]
Offermanns, S. G-proteins as transducers in transmembrane signalling. Prog. Biophys. Mol. Biol. 2003, 83, 101–130. [CrossRef]
Johnston, C.A.; Siderovski, D.P. Receptor-mediated activation of heterotrimeric G-proteins: Current structural insights.
Mol. Pharmacol. 2007, 72, 219–230. [CrossRef]
Milligan, G.; Kostenis, E. Heterotrimeric G-proteins: A short history. Br. J. Pharmacol. 2006, 147 (Suppl. 1), S46–S55. [CrossRef]
Oldham, W.M.; Hamm, H.E. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 2008,
9, 60–71. [CrossRef]
Yoo, J.H.; Shi, D.S.; Grossmann, A.H.; Sorensen, L.K.; Tong, Z.; Mleynek, T.M.; Rogers, A.; Zhu, W.; Richards, J.R.;
Winter, J.M.; et al. ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell
2016, 29, 889–904. [CrossRef]
Wu, D.Q.; Lee, C.H.; Rhee, S.G.; Simon, M.I. Activation of phospholipase C by the alpha subunits of the Gq and G11 proteins in
transfected Cos-7 cells. J. Biol. Chem. 1992, 267, 1811–1817. [CrossRef]
Ross, E.M.; Wilkie, T.M. GTPase-activating proteins for heterotrimeric G proteins: Regulators of G protein signaling (RGS) and
RGS-like proteins. Annu. Rev. Biochem. 2000, 69, 795–827. [CrossRef]
Kimple, A.J.; Bosch, D.E.; Giguère, P.M.; Siderovski, D.P. Regulators of G-protein signaling and their Gα substrates: Promises and
challenges in their use as drug discovery targets. Pharmacol. Rev. 2011, 63, 728–749. [CrossRef]
O’Hayre, M.; Vázquez-Prado, J.; Kufareva, I.; Stawiski, E.W.; Handel, T.M.; Seshagiri, S.; Gutkind, J.S. The emerging mutational
landscape of G proteins and G-protein-coupled receptors in cancer. Nat. Rev. Cancer 2013, 13, 412–424. [CrossRef]
Van Eps, N.; Preininger, A.M.; Alexander, N.; Kaya, A.I.; Meier, S.; Meiler, J.; Hamm, H.E.; Hubbell, W.L. Interaction of a G protein
with an activated receptor opens the interdomain interface in the alpha subunit. Proc. Natl. Acad. Sci. USA 2011, 108, 9420–9424.
[CrossRef]
Kleuss, C.; Raw, A.S.; Lee, E.; Sprang, S.R.; Gilman, A.G. Mechanism of GTP hydrolysis by G-protein alpha subunits. Proc. Natl.
Acad. Sci. USA 1994, 91, 9828–9831. [CrossRef]
Takasaki, J.; Saito, T.; Taniguchi, M.; Kawasaki, T.; Moritani, Y.; Hayashi, K.; Kobori, M. A novel Galphaq/11-selective inhibitor.
J. Biol. Chem. 2004, 279, 47438–47445. [CrossRef]
Weber, A.; Hengge, U.R.; Urbanik, D.; Markwart, A.; Mirmohammadsaegh, A.; Reichel, M.B.; Wittekind, C.; Wiedemann, P.;
Tannapfel, A. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant
melanomas of the uvea. Lab. Investig. 2003, 83, 1771–1776. [CrossRef]
Zuidervaart, W.; van Nieuwpoort, F.; Stark, M.; Dijkman, R.; Packer, L.; Borgstein, A.M.; Pavey, S.; van der Velden, P.; Out, C.;
Jager, M.J.; et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through
mutation of BRAF or RAS. Br. J. Cancer 2005, 92, 2032–2038. [CrossRef]
Edmunds, S.C.; Cree, I.A.; Dí Nícolantonío, F.; Hungerford, J.L.; Hurren, J.S.; Kelsell, D.P. Absence of BRAF gene mutations in
uveal melanomas in contrast to cutaneous melanomas. Br. J. Cancer 2003, 88, 1403–1405. [CrossRef]
Vaqué, J.P.; Dorsam, R.T.; Feng, X.; Iglesias-Bartolome, R.; Forsthoefel, D.J.; Chen, Q.; Debant, A.; Seeger, M.A.; Ksander, B.R.;
Teramoto, H.; et al. A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing mitogenic signals
initiated by G protein-coupled receptors. Mol. Cell 2013, 49, 94–108. [CrossRef]
Babchia, N.; Calipel, A.; Mouriaux, F.; Faussat, A.-M.; Mascarelli, F. The PI3K/Akt and mTOR/P70S6K signaling pathways in
human uveal melanoma cells: Interaction with B-Raf/ERK. Investig. Ophthalmol. Vis. Sci. 2010, 51, 421–429. [CrossRef]

Cancers 2021, 13, 6195

61.
62.
63.

64.
65.

66.

67.

68.

69.

70.

71.

72.
73.
74.
75.
76.

77.
78.

79.

80.

81.
82.

14 of 17

Chua, V.; Lapadula, D.; Randolph, C.; Benovic, J.L.; Wedegaertner, P.B.; Aplin, A.E. Dysregulated GPCR signaling and therapeutic
options in uveal melanoma. Mol. Cancer Res. 2017, 15, 501–506. [CrossRef] [PubMed]
Wu, X.; Li, J.; Zhu, M.; Fletcher, J.A.; Hodi, F.S. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ
mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol. Cancer Ther. 2012, 11, 1905–1914. [CrossRef]
Piperno-Neumann, S.; Kapiteijn, E.; Larkin, J.M.G.; Carvajal, R.D.; Luke, J.J.; Seifert, H.; Roozen, I.; Zoubir, M.; Yang, L.;
Choudhury, S.; et al. Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic
uveal melanoma. J. Clin. Oncol. 2014, 32, 9030. [CrossRef]
Chen, X.; Wu, Q.; Tan, L.; Porter, D.; Jager, M.J.; Emery, C.; Bastian, B.C. Combined PKC and MEK inhibition in uveal melanoma
with GNAQ and GNA11 mutations. Oncogene 2014, 33, 4724–4734. [CrossRef]
Ambrosini, G.; Pratilas, C.A.; Qin, L.-X.; Tadi, M.; Surriga, O.; Carvajal, R.D.; Schwartz, G.K. Identification of unique MEKdependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin. Cancer
Res. 2012, 18, 3552–3561. [CrossRef]
Carvajal, R.D.; Sosman, J.A.; Quevedo, J.F.; Milhem, M.M.; Joshua, A.M.; Kudchadkar, R.R.; Linette, G.P.; Gajewski, T.F.; Lutzky, J.;
Lawson, D.H.; et al. Effect of selumetinib vs. chemotherapy on progression-free survival in uveal melanoma: A randomized
clinical trial. JAMA 2014, 311, 2397–2405. [CrossRef]
Adjei, A.A.; LoRusso, P.; Ribas, A.; Sosman, J.A.; Pavlick, A.C.; Dy, G.K.; Zhou, X.; Gangolli, E.A.; Walker, R.M.; Kneissl, M.; et al.
Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid
tumors. JCO 2013, 31, 2528. [CrossRef]
Carvajal, R.D.; Piperno-Neumann, S.; Kapiteijn, E.; Chapman, P.B.; Frank, S.; Joshua, A.M.; Piulats, J.M.; Wolter, P.; Cocquyt, V.;
Chmielowski, B.; et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A phase III,
multicenter, randomized trial (SUMIT). J. Clin. Oncol. 2018, 36, 1232–1239. [CrossRef]
Kirkwood, J.M.; Bastholt, L.; Robert, C.; Sosman, J.; Larkin, J.; Hersey, P.; Middleton, M.; Cantarini, M.; Zazulina, V.;
Kemsley, K.; et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 2012, 18, 555–567. [CrossRef]
Shoushtari, A.N.; Kudchadkar, R.R.; Panageas, K.; Murthy, R.K.; Jung, M.; Shah, R.; O’Donnell, B.; Khawaja, T.T.; Shames, Y.;
Prempeh-Keteku, N.A.; et al. A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced
uveal melanoma. J. Clin. Oncol. 2016, 34, 9511. [CrossRef]
Falchook, G.S.; Lewis, K.D.; Infante, J.R.; Gordon, M.S.; Vogelzang, N.J.; DeMarini, D.J.; Sun, P.; Moy, C.; Szabo, S.A.;
Roadcap, L.T.; et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation
trial. Lancet Oncol. 2012, 13, 782–789. [CrossRef]
Steeb, T.; Wessely, A.; Ruzicka, T.; Heppt, M.V.; Berking, C. How to MEK the best of uveal melanoma: A systematic review on the
efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. Eur. J. Cancer 2018, 103, 41–51. [CrossRef]
Cheng, H.; Chua, V.; Liao, C.; Purwin, T.J.; Terai, M.; Kageyama, K.; Davies, M.A.; Sato, T.; Aplin, A.E. Co-targeting HGF/cMET
Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Mol. Cancer Ther. 2017, 16, 516–528. [CrossRef]
Cheng, H.; Terai, M.; Kageyama, K.; Ozaki, S.; McCue, P.A.; Sato, T.; Aplin, A.E. Paracrine effect of NRG1 and HGF drives
resistance to MEK inhibitors in metastatic uveal melanoma. Cancer Res. 2015, 75, 2737–2748. [CrossRef]
Decaudin, D.; El Botty, R.; Diallo, B.; Massonnet, G.; Fleury, J.; Naguez, A.; Raymondie, C.; Davies, E.; Smith, A.; Wilson, J.; et al.
Selumetinib-based therapy in uveal melanoma patient-derived xenografts. Oncotarget 2018, 9, 21674–21686. [CrossRef]
Truong, A.; Yoo, J.H.; Scherzer, M.T.; Sanchez, J.M.S.; Dale, K.J.; Kinsey, C.G.; Richards, J.R.; Shin, D.; Ghazi, P.C.;
Onken, M.D.; et al. Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition. Clin. Cancer Res. 2020,
26, 6374–6386. [CrossRef]
Chen, X.; Wu, Q.; Depeille, P.; Chen, P.; Thornton, S.; Kalirai, H.; Coupland, S.E.; Roose, J.P.; Bastian, B.C. Rasgrp3 mediates
MAPK pathway activation in GNAQ mutant uveal melanoma. Cancer Cell 2017, 31, 685–696.e6. [CrossRef]
Moore, A.R.; Ran, L.; Guan, Y.; Sher, J.J.; Hitchman, T.D.; Zhang, J.Q.; Hwang, C.; Walzak, E.G.; Shoushtari, A.N.; Monette, S.; et al.
GNA11 Q209L mouse model reveals RasGRP3 as an essential signaling node in uveal melanoma. Cell Rep. 2018, 22, 2455–2468.
[CrossRef]
Khalili, J.S.; Yu, X.; Wang, J.; Hayes, B.C.; Davies, M.A.; Lizee, G.; Esmaeli, B.; Woodman, S.E. Combination small molecule MEK
and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin. Cancer Res.
2012, 18, 4345–4355. [CrossRef]
Musi, E.; Ambrosini, G.; de Stanchina, E.; Schwartz, G.K. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances
the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Mol. Cancer Ther. 2014,
13, 1044–1053. [CrossRef]
Ambrosini, G.; Musi, E.; Ho, A.L.; de Stanchina, E.; Schwartz, G.K. Inhibition of mutant GNAQ signaling in uveal melanoma
induces AMPK-dependent autophagic cell death. Mol. Cancer Ther. 2013, 12, 768–776. [CrossRef]
Shoushtari, A.N.; Ong, L.T.; Schoder, H.; Singh-Kandah, S.; Abbate, K.T.; Postow, M.A.; Callahan, M.K.; Wolchok, J.;
Chapman, P.B.; Panageas, K.S.; et al. A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic
uveal melanoma. Melanoma Res. 2016, 26, 272–277. [CrossRef]

Cancers 2021, 13, 6195

83.

84.

85.
86.
87.
88.
89.
90.
91.
92.
93.

94.

95.
96.
97.
98.
99.

100.

101.

102.

103.

104.
105.

106.
107.
108.

15 of 17

Amirouchene-Angelozzi, N.; Frisch-Dit-Leitz, E.; Carita, G.; Dahmani, A.; Raymondie, C.; Liot, G.; Gentien, D.; Némati, F.;
Decaudin, D.; Roman-Roman, S.; et al. The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance
anti-tumor efficacy in uveal melanoma. Oncotarget 2016, 7, 23633–23646. [CrossRef]
Carita, G.; Frisch-Dit-Leitz, E.; Dahmani, A.; Raymondie, C.; Cassoux, N.; Piperno-Neumann, S.; Némati, F.; Laurent, C.;
De Koning, L.; Halilovic, E.; et al. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient
therapeutic approaches for uveal melanoma. Oncotarget 2016, 7, 33542–33556. [CrossRef]
Zhang, K.; Qi, H.-X.; Hu, Z.-M.; Chang, Y.-N.; Shi, Z.-M.; Han, X.-H.; Han, Y.-W.; Zhang, R.-X.; Zhang, Z.; Chen, T.; et al. YAP and
TAZ take center stage in cancer. Biochemistry 2015, 54, 6555–6566. [CrossRef]
Liu-Chittenden, Y.; Huang, B.; Shim, J.S.; Chen, Q.; Lee, S.-J.; Anders, R.A.; Liu, J.O.; Pan, D. Genetic and pharmacological
disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012, 26, 1300–1305. [CrossRef]
Pan, D. The hippo signaling pathway in development and cancer. Dev. Cell 2010, 19, 491–505. [CrossRef]
Ramos, A.; Camargo, F.D. The Hippo signaling pathway and stem cell biology. Trends Cell Biol. 2012, 22, 339–346. [CrossRef]
Yu, F.-X.; Guan, K.-L. The Hippo pathway: Regulators and regulations. Genes Dev. 2013, 27, 355–371. [CrossRef]
Lyubasyuk, V.; Ouyang, H.; Yu, F.-X.; Guan, K.-L.; Zhang, K. YAP inhibition blocks uveal melanogenesis driven by GNAQ or
GNA11 mutations. Mol. Cell. Oncol. 2015, 2, e970957. [CrossRef]
Kim, Y.J.; Lee, S.C.; Kim, S.E.; Kim, S.H.; Kim, S.K.; Lee, C.S. YAP Activity is Not Associated with Survival of Uveal Melanoma
Patients and Cell Lines. Sci. Rep. 2020, 10, 6209. [CrossRef]
Brouwer, N.J.; Konstantinou, E.K.; Gragoudas, E.S.; Marinkovic, M.; Luyten, G.P.M.; Kim, I.K.; Jager, M.J.; Vavvas, D.G. Targeting
the YAP/TAZ pathway in uveal and conjunctival melanoma with verteporfin. Investig. Ophthalmol. Vis. Sci. 2021, 62, 3. [CrossRef]
Feng, X.; Arang, N.; Rigiracciolo, D.C.; Lee, J.S.; Yeerna, H.; Wang, Z.; Lubrano, S.; Kishore, A.; Pachter, J.A.; König, G.M.; et al. A
Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo
Pathway through FAK. Cancer Cell 2019, 35, 457–472.e5. [CrossRef]
Paradis, J.S.; Acosta, M.; Saddawi-Konefka, R.; Kishore, A.; Gomes, F.; Arang, N.; Tiago, M.; Coma, S.; Lubrano, S.; Wu, X.; et al.
Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal
Melanoma. Clin. Cancer Res. 2021, 27, 3190–3200. [CrossRef]
Ma, J.; Weng, L.; Bastian, B.C.; Chen, X. Functional characterization of uveal melanoma oncogenes. Oncogene 2021, 40, 806–820.
[CrossRef]
Shain, A.H.; Bagger, M.M.; Yu, R.; Chang, D.; Liu, S.; Vemula, S.; Weier, J.F.; Wadt, K.; Heegaard, S.; Bastian, B.C.; et al. The genetic
evolution of metastatic uveal melanoma. Nat. Genet. 2019, 51, 1123–1130. [CrossRef]
Zhang, H.; Nielsen, A.L.; Strømgaard, K. Recent achievements in developing selective Gq inhibitors. Med. Res. Rev. 2020,
40, 135–157. [CrossRef]
Kostenis, E.; Pfeil, E.M.; Annala, S. Heterotrimeric Gq proteins as therapeutic targets? J. Biol. Chem. 2020, 295, 5206–5215.
[CrossRef]
Taniguchi, M.; Nagai, K.; Arao, N.; Kawasaki, T.; Saito, T.; Moritani, Y.; Takasaki, J.; Hayashi, K.; Fujita, S.; Suzuki, K.; et al.
YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666. J. Antibiot. 2003, 56, 358–363.
[CrossRef]
Uemura, T.; Kawasaki, T.; Taniguchi, M.; Moritani, Y.; Hayashi, K.; Saito, T.; Takasaki, J.; Uchida, W.; Miyata, K. Biological
properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
Br. J. Pharmacol. 2006, 148, 61–69. [CrossRef]
Kawasaki, T.; Taniguchi, M.; Moritani, Y.; Uemura, T.; Shigenaga, T.; Takamatsu, H.; Hayashi, K.; Takasaki, J.; Saito, T.; Nagai, K.
Pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on thrombosis and neointima formation in mice.
Thromb. Haemost. 2005, 94, 184–192. [CrossRef]
Kawasaki, T.; Taniguchi, M.; Moritani, Y.; Hayashi, K.; Saito, T.; Takasaki, J.; Nagai, K.; Inagaki, O.; Shikama, H. Antithrombotic
and thrombolytic efficacy of YM-254890, a G q/11 inhibitor, in a rat model of arterial thrombosis. Thromb. Haemost. 2003,
90, 406–413. [CrossRef] [PubMed]
Xiong, X.-F.; Zhang, H.; Underwood, C.R.; Harpsøe, K.; Gardella, T.J.; Wöldike, M.F.; Mannstadt, M.; Gloriam, D.E.; BräunerOsborne, H.; Strømgaard, K. Total synthesis and structure-activity relationship studies of a series of selective G protein inhibitors.
Nat. Chem. 2016, 8, 1035–1041. [CrossRef]
Fujioka, M.; Koda, S.; Morimoto, Y.; Biemann, K. Structure of FR900359, a cyclic depsipeptide from Ardisia crenata sims. J. Org.
Chem. 1988, 53, 2820–2825. [CrossRef]
Carlier, A.; Fehr, L.; Pinto-Carbó, M.; Schäberle, T.; Reher, R.; Dessein, S.; König, G.; Eberl, L. The genome analysis of Candidatus
Burkholderia crenata reveals that secondary metabolism may be a key function of the Ardisia crenata leaf nodule symbiosis.
Environ. Microbiol. 2016, 18, 2507–2522. [CrossRef]
Inamdar, V.; Patel, A.; Manne, B.K.; Dangelmaier, C.; Kunapuli, S.P. Characterization of UBO-QIC as a Gαq inhibitor in platelets.
Platelets 2015, 26, 771–778. [CrossRef]
Schrage, R.; Schmitz, A.-L.; Gaffal, E.; Annala, S.; Kehraus, S.; Wenzel, D.; Büllesbach, K.M.; Bald, T.; Inoue, A.; Shinjo, Y.; et al.
The experimental power of FR900359 to study Gq-regulated biological processes. Nat. Commun. 2015, 6, 10156. [CrossRef]
Zaima, K.; Deguchi, J.; Matsuno, Y.; Kaneda, T.; Hirasawa, Y.; Morita, H. Vasorelaxant effect of FR900359 from Ardisia crenata on
rat aortic artery. J. Nat. Med. 2013, 67, 196–201. [CrossRef] [PubMed]

Cancers 2021, 13, 6195

16 of 17

109. Carr, R.; Koziol-White, C.; Zhang, J.; Lam, H.; An, S.S.; Tall, G.G.; Panettieri, R.A.; Benovic, J.L. Interdicting Gq Activation in
Airway Disease by Receptor-Dependent and Receptor-Independent Mechanisms. Mol. Pharmacol. 2016, 89, 94–104. [CrossRef]
110. Gao, Z.-G.; Jacobson, K.A. On the selectivity of the Gαq inhibitor UBO-QIC: A comparison with the Gαi inhibitor pertussis toxin.
Biochem. Pharmacol. 2016, 107, 59–66. [CrossRef]
111. Pfeil, E.M.; Brands, J.; Merten, N.; Vögtle, T.; Vescovo, M.; Rick, U.; Albrecht, I.-M.; Heycke, N.; Kawakami, K.; Ono, Y.; et al.
Heterotrimeric G Protein Subunit Gαq Is a Master Switch for Gβγ-Mediated Calcium Mobilization by Gi-Coupled GPCRs.
Mol. Cell 2020, 80, 940–954.e6. [CrossRef] [PubMed]
112. Crüsemann, M.; Reher, R.; Schamari, I.; Brachmann, A.O.; Ohbayashi, T.; Kuschak, M.; Malfacini, D.; Seidinger, A.; Pinto-Carbó,
M.; Richarz, R.; et al. Heterologous Expression, Biosynthetic Studies, and Ecological Function of the Selective Gq-Signaling
Inhibitor FR900359. Angew. Chem. Int. Ed. Engl. 2018, 57, 836–840. [CrossRef] [PubMed]
113. Pistorius, D.; Buntin, K.; Bouquet, C.; Richard, E.; Weber, E.; Wollbrett, S. Genetic Engineering of Chromobacterium vaccinii DSM
25150 for Improved Production of FR900359; ChemRxiv; Cambridge Open Engage: Cambridge, UK, 2021; This content is a preprint
and has not been peer-reviewed. [CrossRef]
114. Nishimura, A.; Kitano, K.; Takasaki, J.; Taniguchi, M.; Mizuno, N.; Tago, K.; Hakoshima, T.; Itoh, H. Structural basis for the
specific inhibition of heterotrimeric Gq protein by a small molecule. Proc. Natl. Acad. Sci. USA 2010, 107, 13666–13671. [CrossRef]
[PubMed]
115. Malfacini, D.; Patt, J.; Annala, S.; Harpsøe, K.; Eryilmaz, F.; Reher, R.; Crüsemann, M.; Hanke, W.; Zhang, H.; Tietze, D.; et al.
Rational design of a heterotrimeric G protein α subunit with artificial inhibitor sensitivity. J. Biol. Chem. 2019, 294, 5747–5758.
[CrossRef]
116. Zhang, H.; Nielsen, A.L.; Boesgaard, M.W.; Harpsøe, K.; Daly, N.L.; Xiong, X.-F.; Underwood, C.R.; Haugaard-Kedström, L.M.;
Bräuner-Osborne, H.; Gloriam, D.E.; et al. Structure-activity relationship and conformational studies of the natural product cyclic
depsipeptides YM-254890 and FR900359. Eur. J. Med. Chem. 2018, 156, 847–860. [CrossRef] [PubMed]
117. Kuschak, M.; Namasivayam, V.; Rafehi, M.; Voss, J.H.; Garg, J.; Schlegel, J.G.; Abdelrahman, A.; Kehraus, S.; Reher, R.;
Küppers, J.; et al. Cell-permeable high-affinity tracers for Gq proteins provide structural insights, reveal distinct binding kinetics
and identify small molecule inhibitors. Br. J. Pharmacol. 2020, 177, 1898–1916. [CrossRef]
118. Lapadula, D.; Farias, E.; Randolph, C.E.; Purwin, T.J.; McGrath, D.; Charpentier, T.H.; Zhang, L.; Wu, S.; Terai, M.; Sato, T.; et al.
Effects of oncogenic Gαq and Gα11 inhibition by FR900359 in uveal melanoma. Mol. Cancer Res. 2019, 17, 963–973. [CrossRef]
119. Onken, M.D.; Makepeace, C.M.; Kaltenbronn, K.M.; Kanai, S.M.; Todd, T.D.; Wang, S.; Broekelmann, T.J.; Rao, P.K.; Cooper, J.A.;
Blumer, K.J. Targeting nucleotide exchange to inhibit constitutively active G protein α subunits in cancer cells. Sci. Signal. 2018,
11, 546. [CrossRef]
120. Annala, S.; Feng, X.; Shridhar, N.; Eryilmaz, F.; Patt, J.; Yang, J.; Pfeil, E.M.; Cervantes-Villagrana, R.D.; Inoue, A.;
Häberlein, F.; et al. Direct targeting of Gαq and Gα11 oncoproteins in cancer cells. Sci. Signal. 2019, 12, 573. [CrossRef]
121. Onken, M.D.; Makepeace, C.M.; Kaltenbronn, K.M.; Choi, J.; Hernandez-Aya, L.; Weilbaecher, K.N.; Piggott, K.D.; Rao, P.K.;
Yuede, C.M.; Dixon, A.J.; et al. Targeting primary and metastatic uveal melanoma with a Gprotein inhibitor. J. Biol. Chem. 2021,
296, 100403. [CrossRef]
122. Hitchman, T.D.; Bayshtok, G.; Ceraudo, E.; Moore, A.R.; Lee, C.; Jia, R.; Wang, N.; Pachai, M.R.; Shoushtari, A.N.;
Francis, J.H.; et al. Combined inhibition of Gαq and MEK enhances therapeutic efficacy in uveal melanoma. Clin. Cancer Res.
2021, 27, 1476–1490. [CrossRef]
123. Schlegel, J.G.; Tahoun, M.; Seidinger, A.; Voss, J.H.; Kuschak, M.; Kehraus, S.; Schneider, M.; Matthey, M.; Fleischmann, B.K.;
König, G.M.; et al. Macrocyclic Gq Protein Inhibitors FR900359 and/or YM-254890-Fit for Translation? ACS Pharmacol. Transl. Sci.
2021, 4, 888–897. [CrossRef] [PubMed]
124. Onken, M.D.; Worley, L.A.; Ehlers, J.P.; Harbour, J.W. Gene expression profiling in uveal melanoma reveals two molecular classes
and predicts metastatic death. Cancer Res. 2004, 64, 7205–7209. [CrossRef]
125. Bauer, J.; Kilic, E.; Vaarwater, J.; Bastian, B.C.; Garbe, C.; de Klein, A. Oncogenic GNAQ mutations are not correlated with
disease-free survival in uveal melanoma. Br. J. Cancer 2009, 101, 813–815. [CrossRef]
126. Offermanns, S.; Hashimoto, K.; Watanabe, M.; Sun, W.; Kurihara, H.; Thompson, R.F.; Inoue, Y.; Kano, M.; Simon, M.I. Impaired
motor coordination and persistent multiple climbing fiber innervation of cerebellar Purkinje cells in mice lacking Galphaq.
Proc. Natl. Acad. Sci. USA 1997, 94, 14089–14094. [CrossRef]
127. Offermanns, S.; Zhao, L.P.; Gohla, A.; Sarosi, I.; Simon, M.I.; Wilkie, T.M. Embryonic cardiomyocyte hypoplasia and craniofacial
defects in G alpha q/G alpha 11-mutant mice. EMBO J. 1998, 17, 4304–4312. [CrossRef] [PubMed]
128. Frederick, A.L.; Saborido, T.P.; Stanwood, G.D. Neurobehavioral phenotyping of Gαq knockout mice reveals impairments in
motor functions and spatial working memory without changes in anxiety or behavioral despair. Front. Behav. Neurosci. 2012, 6, 29.
[CrossRef] [PubMed]
129. Wiesen, K.; Kaiser, E.; Schröder, L.; Scholz, A.; Ruppenthal, S.; Reil, J.-C.; Backes, C.; Meese, E.; Meier, C.; Bogdanova, A.; et al.
Cardiac remodeling in Gαq and Gα11 knockout mice. Int. J. Cardiol. 2016, 202, 836–845. [CrossRef] [PubMed]
130. Rensing, D.T.; Uppal, S.; Blumer, K.J.; Moeller, K.D. Toward the Selective Inhibition of G Proteins: Total Synthesis of a Simplified
YM-254890 Analog. Org. Lett. 2015, 17, 2270–2273. [CrossRef]
131. Kaur, H.; Harris, P.W.R.; Little, P.J.; Brimble, M.A. Total synthesis of the cyclic depsipeptide YM-280193, a platelet aggregation
inhibitor. Org. Lett. 2015, 17, 492–495. [CrossRef]

Cancers 2021, 13, 6195

17 of 17

132. Zhang, H.; Xiong, X.-F.; Boesgaard, M.W.; Underwood, C.R.; Bräuner-Osborne, H.; Strømgaard, K. Structure-Activity Relationship
Studies of the Cyclic Depsipeptide Natural Product YM-254890, Targeting the Gq Protein. Chem. Med. Chem. 2017, 12, 830–834.
[CrossRef]
133. Xiong, X.-F.; Zhang, H.; Boesgaard, M.W.; Underwood, C.R.; Bräuner-Osborne, H.; Strømgaard, K. Structure-Activity Relationship
Studies of the Natural Product Gq/11 Protein Inhibitor YM-254890. Chem. Med. Chem. 2019, 14, 865–870. [CrossRef] [PubMed]
134. Reher, R.; Kühl, T.; Annala, S.; Benkel, T.; Kaufmann, D.; Nubbemeyer, B.; Odhiambo, J.P.; Heimer, P.; Bäuml, C.A.;
Kehraus, S.; et al. Deciphering Specificity Determinants for FR900359-Derived Gq α Inhibitors Based on Computational and
Structure-Activity Studies. Chem. Med. Chem. 2018, 13, 1634–1643. [CrossRef] [PubMed]
135. Reher, R.; Kuschak, M.; Heycke, N.; Annala, S.; Kehraus, S.; Dai, H.-F.; Müller, C.E.; Kostenis, E.; König, G.M.; Crüsemann, M.
Applying molecular networking for the detection of natural sources and analogues of the selective Gq protein inhibitor FR900359.
J. Nat. Prod. 2018, 81, 1628–1635. [CrossRef]
136. Hermes, C.; Richarz, R.; Wirtz, D.A.; Patt, J.; Hanke, W.; Kehraus, S.; Voß, J.H.; Küppers, J.; Ohbayashi, T.; Namasivayam, V.; et al.
Thioesterase-mediated side chain transesterification generates potent Gq signaling inhibitor FR900359. Nat. Commun. 2021,
12, 144. [CrossRef]
137. Hanke, W.; Patt, J.; Alenfelder, J.; Voss, J.H.; Zdouc, M.M.; Kehraus, S.; Kim, J.B.; Grujičić, G.V.; Namasivayam, V.; Reher, R.; et al.
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